HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead
The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."
Overview
The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.